MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Waters Corporation DPO Ratio 2011-2026 | WAT
Annual DPO Ratio Waters Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 | 96.7 | 102 | 99.6 | 87.9 | 22 | 17.7 | 25.1 | 24.9 | 27.7 | 30.6 | 29.1 | 30.3 | 27.1 | 27.6 | 31.8 | 29.7 | 13 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 | 13 | 45.8 |
Quarterly DPO Ratio Waters Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 59.4 | 55.5 | 60.5 | - | - | - | - | - | - | - | - | - | - | - | - | 24.1 | 29 | 26.8 | 27.6 | 20.6 | 25.1 | 30.9 | 26.2 | 14.9 | 18.6 | 17.9 | 24.2 | 21.7 | 25.8 | 25.6 | 27.3 | 21.8 | 25 | 25.6 | 28.6 | 24.6 | 28.3 | 28.1 | 31.4 | 27.1 | 31.1 | 30.9 | 32.9 | 25.7 | 29.6 | 29.7 | 31.8 | 25.9 | 30.9 | 31.5 | 31.3 | 24 | 27.3 | 27.9 | 30 | 24.7 | 28 | 28.7 | 31.9 | 34.3 | 34.5 | 33.8 | 30.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 60.5 | 14.9 | 29.2 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
Fulgent Genetics
FLGT
|
35.2 | $ 19.5 | 7.5 % | $ 600 M | USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.24 K | $ 5.76 | 11.41 % | $ 7.66 M | USA |
 |
Castle Biosciences
CSTL
|
65.8 | $ 21.6 | 5.93 % | $ 626 M | USA |
 |
Aspira Women's Health
AWH
|
189 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
196 | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
48.6 | $ 133.06 | 4.75 % | $ 16.7 B | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
ICON Public Limited Company
ICLR
|
11 | $ 152.8 | 6.18 % | $ 12 B |  Irlanda |
 |
CareDx, Inc
CDNA
|
44.2 | $ 23.12 | 3.63 % | $ 1.23 B | USA |
 |
Illumina
ILMN
|
57.1 | $ 168.06 | -1.68 % | $ 26 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Interpace Biosciences
IDXG
|
33 | $ 1.79 | 2.29 % | $ 7.92 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
Mettler-Toledo International
MTD
|
53.4 | - | - | $ 24.3 B |  Schweiz |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
23.6 | - | - | $ 6.94 B | USA |
 |
NeoGenomics
NEO
|
19.7 | $ 11.31 | 11.54 % | $ 1.45 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 185.79 | 3.29 % | $ 9.21 B | USA |
 |
Natera
NTRA
|
17.9 | $ 222.1 | 4.84 % | $ 30.4 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 458.69 | 1.75 % | $ 13.2 B | USA |
 |
Exact Sciences Corporation
EXAS
|
49.2 | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 19.75 | 3.73 % | $ 442 M | USA |
 |
Myriad Genetics
MYGN
|
45.9 | $ 4.69 | 6.59 % | $ 434 M | USA |
 |
Personalis
PSNL
|
65.7 | $ 12.1 | 12.24 % | $ 1.08 B | USA |
 |
Senseonics Holdings
SENS
|
68 | $ 7.01 | 4.32 % | $ 293 M | USA |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
1.44 K | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
32.4 | - | - | $ 4.94 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 260.97 | 0.79 % | $ 21.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
12.5 | - | - | $ 4.42 B | USA |
 |
Thermo Fisher Scientific
TMO
|
49.3 | $ 482.03 | 1.7 % | $ 182 B | USA |
 |
Trinity Biotech plc
TRIB
|
163 | $ 0.68 | -2.4 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
62.7 | $ 9.12 | 3.52 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 196.12 | 1.27 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | USA |